Cited by 752Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismLipid metabolism and disorders

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

Open access

Cannon, Christopher P., Shah, Sukrut, Dansky, Hayes M., Davidson, Michael, Brinton, Eliot A., Gotto, Antonio M., Stepanavage, Michael, Liu, Sherry Xueyu, Gibbons, Patrice, Ashraf, Tanya B., Zafarino, Jennifer, Mitchel, Yale, Barter, Philip·2010·New England Journal of Medicine

DOI 10.1056/nejmoa1009744

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease. Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent with that recommended in guidelines were assigned to receive 100 mg of anacetrapib or placebo daily for 18 months. The primary end points were the percent change from baseline in LDL cholesterol at 24 weeks (HDL cholesterol level was a secondary end point) and the safety and side-effect profile of anacetrapib through 76 weeks. Cardiovascular events and deaths were prospectively adjudicated. RESULTS: A total of 1623 patients underwent randomization. By 24 weeks, the LDL cholesterol level had been reduced from 81 mg per deciliter (2.1 mmol per liter) to 45 mg per deciliter (1.2 mmol per liter) in the anacetrapib group, as compared with a reduction from 82 mg per deciliter (2.1 mmol per liter) to 77 mg per deciliter (2.0 mmol per liter) in the placebo group (P<0.001)--a 39.8% reduction with anacetrapib beyond that seen with placebo. In addition, the HDL cholesterol level increased from 41 mg per deciliter (1.0 mmol per liter) to 101 mg per deciliter (2.6 mmol per liter) in the anacetrapib group, as compared with an increase from 40 mg per deciliter (1.0 mmol per liter) to 46 mg per deciliter (1.2 mmol per liter) in the placebo group (P<0.001)--a 138.1% increase with anacetrapib beyond that seen with placebo. Through 76 weeks, no changes were noted in blood pressure or electrolyte or aldosterone levels with anacetrapib as compared with placebo. Prespecified adjudicated cardiovascular events occurred in 16 patients treated with anacetrapib (2.0%) and 21 patients receiving placebo (2.6%) (P = 0.40). The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib. CONCLUSIONS: Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib. (Funded by Merck Research Laboratories; ClinicalTrials.gov number, NCT00685776.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1009744

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citation
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citation
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Torcetrapib‐induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
Forrest, M. J., Bloomfield, D. M., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.229 · Cited by 293
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Krishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M. S., Côté, J., Rosko, K., Chavez-Eng, C. M., Lutz, R., Bloomfield, D. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61813-3 · Cited by 275

Flagged first, then by citations

Show all 17 references

Sorted by citations

Items 201–300 of 752

Recent Clinical Studies of the Effects of Lipid-Modifying Therapies
Gotto, A. M., & Moon, J. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.003 · Cited by 44
Self-citation
Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia
Poliakova, T., & Wellington, C. L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00671-y · Cited by 42
New Therapies for Reducing Low-Density Lipoprotein Cholesterol
Stein, E. A., & Raal, F. J. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.008 · Cited by 42
High-Fat and Fructose Intake Induces Insulin Resistance, Dyslipidemia, and Liver Steatosis and Alters In Vivo Macrophage-to-Feces Reverse Cholesterol Transport in Hamsters
Briand, F., Thiéblemont, Q., Muzotte, E., & Sulpice, T. (2012) · Journal of Nutrition · doi:10.3945/jn.111.153197 · Cited by 42
High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis
Favari, E., Thomas, M. J., & Sorci‐Thomas, M. G. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000573 · Cited by 42
Screening and treatment of familial hypercholesterolemia – Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014)
Besseling, J., Sjouke, B., & Kastelein, J. J. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.011 · Cited by 41
Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians
Rashid, S., Sniderman, A. D., Melone, M., Brown, P. E., Otvos, J. D., Mente, A., Schulze, K. M., McQueen, M., Anand, S. S., & Yusuf, S. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314528461 · Cited by 41
Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses
van Capelleveen, J. C., Kastelein, J. J. P., Zwinderman, A. H., van Deventer, S. J. H., Collins, H. L., Adelman, S. J., Round, P., Ford, J., Rader, D. J., & Hovingh, G. K. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.006 · Cited by 42
High-Density Lipoproteins
Zheng, C., & Aikawa, M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.999 · Cited by 42
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Do, R. Q., Vogel, R. A., & Schwartz, G. G. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0345-z · Cited by 41
Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention
Konishi, H., Miyauchi, K., Tsuboi, S., Ogita, M., Naito, R., Dohi, T., Kasai, T., Tamura, H., Okazaki, S., Isoda, K., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.12.007 · Cited by 40
Structural Insights into High Density Lipoprotein: Old Models and New Facts
Gogonea, V. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00318 · Cited by 41
HDL cholesterol and clinical outcomes in diabetes mellitus
Ishibashi, T., Kaneko, H., Matsuoka, S., Suzuki, Y., Ueno, K., Ohno, R., Okada, A., Fujiu, K., Michihata, N., Jo, T., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad029 · Cited by 39
HDL Metabolism and Atheroprotection
Maranhão, R. C., & Freitas, F. R. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800141-7.00001-2 · Cited by 40
Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein
Reyes‐Soffer, G., Millar, J. S., Ngai, C. I., Jumes, P. A., Coromilas, E. J., Asztalos, B. F., Johnson‐Levonas, A. O., Wagner, J. A., Donovan, D. S., Karmally, W., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306680 · Cited by 38
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
Girona, J., Ibarretxe, D., Plana, N., Guaita‐Esteruelas, S., Amigó, N., Heras, M., & Masana, L. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0428-z · Cited by 38
Protective effect of HSP27 in atherosclerosis and coronary heart disease by inhibiting reactive oxygen species
Zhang, H., Jia, K., Da Yu, S. U. N., & Yang, M. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26575 · Cited by 39
Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator
Boffa, M. B., & Koschinsky, M. L. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0360-6 · Cited by 38
Update on the Discovery and Development of Cholesteryl Ester Transfer Protein Inhibitors for Reducing Residual Cardiovascular Risk
Mantlo, N. B., & Escribano, A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400574e · Cited by 37
Analysis of in vitrobioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds
Southan, C., Boppana, K., Jagarlapudi, S. A. R. P., & Mureşan, S. (2011) · Journal of Cheminformatics · doi:10.1186/1758-2946-3-14 · Cited by 37
The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update
Katsiki, N., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660673 · Cited by 37
Impact of Modifiable Cardiovascular Risk Factors on Mortality After Percutaneous Coronary Intervention
Bundhun, P. K., Wu, Z. J., & Chen, M. (2015) · Medicine · doi:10.1097/md.0000000000002313 · Cited by 37
Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol
Wright, R. S. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328362059d · Cited by 37
Lipid efflux mechanisms, relation to disease and potential therapeutic aspects
Castaño, D., Rattanasopa, C., Monteiro-Cardoso, V. F., Corlianò, M., Liu, Y., Zhong, A., Rusu, M., Liehn, E. A., & Singaraja, R. R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.013 · Cited by 37
Statin intolerance
Laufs, U., Scharnagl, H., & März, W. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000236 · Cited by 39
Structure-based mechanism and inhibition of cholesteryl ester transfer protein
Han, X. M., Zhang, M., Liu, J., Wang, J., & Ren, G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01087-1 · Cited by 37
The Repeated Setbacks of HIV Vaccine Development Laid the Groundwork for SARS-CoV-2 Vaccines
Harris, J. E. (2021) · National Bureau of Economic Research · doi:10.3386/w28587 · Cited by 37
Implications of reverse cholesterol transport: Recent studies
Levinson, S. S., & Wagner, S. G. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.018 · Cited by 36
A Vaccine Targeted at CETP Alleviates High Fat and High Cholesterol Diet-Induced Atherosclerosis and Non-Alcoholic Steatohepatitis in Rabbit
Liaw, Y.-W., Lin, C.-Y., Lai, Y.-S., Yang, T.-C., Wang, C., Whang‐Peng, J., Liu, L. F., Lin, C.-P., Nieh, S., Lu, S.-C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111529 · Cited by 36
Effect of Serum Lipid Levels on Stroke Outcome after rt-PA Therapy: SAMURAI rt-PA Registry
Makihara, N., Okada, Y., Koga, M., Shiokawa, Y., Nakagawara, J., Furui, E., Kimura, K., Yamagami, H., Hasegawa, Y., Kario, K., et al. (2012) · Cerebrovascular Diseases · doi:10.1159/000334664 · Cited by 37
An In-Silico Model of Lipoprotein Metabolism and Kinetics for the Evaluation of Targets and Biomarkers in the Reverse Cholesterol Transport Pathway
Lu, J. J.-Q., Hübner, K., Nanjee, M. N., Brinton, E. A., & Mazer, N. A. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003509 · Cited by 37
Self-citation
Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults
Suico, J. G., Wang, M., Friedrich, S. W., Cannady, E. A., Konkoy, C. S., Ruotolo, G., & Krueger, K. A. (2014) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12287 · Cited by 36
Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead—Pro
Barter, P. J., & Rye, K. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306879 · Cited by 36
Self-citation
New directions for pharmacotherapy in the treatment of acute coronary syndrome
Adamski, P., Adamska, U., Ostrowska, M., Koziński, M., & Kubica, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241234 · Cited by 36
CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet
Zhu, L., Luu, T. N., Emfinger, C. H., Parks, B. A., Shi, J., Trefts, E., Zeng, F., Kuklenyik, Z., Harris, R. C., Wasserman, D. H., et al. (2018) · Diabetes · doi:10.2337/db18-0474 · Cited by 36
ApoC2 deficiency elicits severe hypertriglyceridemia and spontaneous atherosclerosis: A rodent model rescued from neonatal death
Gao, M., Yang, C., Wang, X., Guo, M., Liu, Y., Gao, S., Zhang, X., Ruan, G., Li, X., Tian, W., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154296 · Cited by 36
Recent advances in the pharmacological management of hypercholesterolaemia
Ajufo, E., & Rader, D. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00074-7 · Cited by 36
Why Targeting HDL Should Work as a Therapeutic Tool, but Has Not
Sorci‐Thomas, M. G., & Thomas, M. J. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31829d48a5 · Cited by 35
An evaluation of RVX-208 for the treatment of atherosclerosis
Nikolić, D., Rizzo, M., Mikhailidis, D. P., Wong, N. C. W., & Banach, M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1083010 · Cited by 36
Novel Therapies Focused on the High-Density Lipoprotein Particle
van Capelleveen, J. C., Brewer, H. B., Kastelein, J. J. P., & Hovingh, G. K. (2014) · Circulation Research · doi:10.1161/circresaha.114.301804 · Cited by 34
Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children
Page, M. M., Bell, D. A., Hooper, A. J., Watts, G. F., & Burnett, J. R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.004 · Cited by 35
Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?
Barter, P. J., & Rye, K. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.021 · Cited by 35
Self-citation
Therapeutic Approaches to the Regulation of Metabolism of High-Density Lipoprotein
Zhang, B., Kawachi, E., Miura, S.-I., Uehara, Y., Matsunaga, A., Kuroki, M., & Saku, K. (2013) · Circulation Journal · doi:10.1253/circj.cj-12-1584 · Cited by 34
Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism
Schaefer, E. J. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283612454 · Cited by 34
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9
van der Tuin, S. J. L., Kühnast, S., Berbée, J. F. P., Verschuren, L., Pieterman, E. J., Havekes, L. M., van der Hoorn, J. W. A., Rensen, P. C. N., Jukema, J. W., Princen, H. M. G., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m057794 · Cited by 33
Cholesteryl ester transfer protein inhibitors: challenges and perspectives
Filippatos, T. D., Klouras, E., Barkas, F., & Elisaf, M. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1189327 · Cited by 34
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 33
Relation between plasma and brain lipids
Wellington, C. L., & Frikke-Schmidt, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000291 · Cited by 33
Lipoprotein(a) in clinical practice: New perspectives from basic and translational science
Scipione, C. A., Koschinsky, M. L., & Boffa, M. B. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1415866 · Cited by 34
PCSK9 Inhibition
Vogel, R. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.011 · Cited by 33
Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?
Larach, D. B., deGoma, E. M., & Rader, D. J. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0317-3 · Cited by 33
Lipoprotein (a): When to Measure and How to Treat?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00951-2 · Cited by 32
Effects of HDL-modifiers on cardiovascular outcomes: A meta-analysis of randomized trials
Verdoia, M., Schaffer, A., Suryapranata, H., & Luca, G. D. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.09.003 · Cited by 33
A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs
Alla, V. M., Agrawal, V., DeNazareth, A., Mohiuddin, S., Ravilla, S., & Rendell, M. (2013) · Drugs · doi:10.1007/s40265-013-0072-9 · Cited by 33
Disorders of Lipid Metabolism
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 32
CETP
Tardif, J., Rhainds, D., Rhéaume, É., & Dubé, M. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307122 · Cited by 32
Segregation of LIPG, CETP, and GALNT2 Mutations in Caucasian Families with Extremely High HDL Cholesterol
Tietjen, I., Hovingh, G. K., Singaraja, R. R., Radomski, C., Barhdadi, A., McEwen, J., Chan, E., Mattice, M., Legendre, A., Franchini, P. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037437 · Cited by 31
Emerging therapeutic strategies to enhance HDL function
Redondo, S., Martínez‐González, J., Urraca, C., & Tejerina, T. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-175 · Cited by 31
Drug development in the light of translational science: shine or shade?
Wehling, M. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.07.008 · Cited by 32
Extended‐release niacin increases anti‐apolipoprotein A‐I antibodies that block the antioxidant effect of high‐density lipoprotein–cholesterol: the EXPLORE clinical trial
Batuca, J. R., Amaral, M., Favas, C., Paula, F. S., Ames, P. R. J., Papoila, A. L., & Alves, J. D. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13198 · Cited by 31
ETC-216 for coronary artery disease
Nicholls, S. J., Uno, K., Kataoka, Y., & Nissen, S. E. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.557061 · Cited by 31
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia
Teramoto, T., Shirakawa, M., Kikuchi, M., Nakagomi, M., Tamura, S., Surks, H. K., Sisk, C. M., & Numaguchi, H. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.05.012 · Cited by 30
Therapeutic strategies to deplete macrophages in atherosclerotic plaques
Meyer, I. D., Martinet, W., & Meyer, G. R. Y. D. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04211.x · Cited by 31
HDL particle functionality as a primary pharmacological target for HDL-based therapies
Kypreos, K. E., Gkizas, S., Rallidis, L. S., & Karagiannides, I. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.004 · Cited by 30
HDL-C: clinical equipoise and vascular endothelial function
Campbell, S., & Genest, J. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.17 · Cited by 30
Current guidelines for high-density lipoprotein cholesterol in therapy and future directions
Michos, E. D., Subedi, B. H., Joshi, P. H., Jones, S. R., Martin, S. S., & Blaha, M. J. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s45648 · Cited by 31
Modulation of lipid metabolism with the overexpression of NPC1L1 in mouse liver
Kurano, M., Hara, M., Tsuneyama, K., Okamoto, K., Iso-O, N., Matsushima, T., Koike, K., & Tsukamoto, K. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m026575 · Cited by 30
Plaque imaging to refine indications for emerging lipid-lowering drugs
Alkhalil, M., Chai, J. T., & Choudhury, R. P. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw034 · Cited by 30
Efficacy, Safety, Tolerability, and Pharmacokinetic Profile of Evacetrapib Administered as Monotherapy or in Combination With Atorvastatin in Japanese Patients With Dyslipidemia
Teramoto, T., Takeuchi, M., Morisaki, Y., Ruotolo, G., & Krueger, K. A. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.03.045 · Cited by 29
Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme
Landmesser, U., von Eckardstein, A., Kastelein, J. J. P., Deanfield, J. E., & Lüscher, T. F. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs182 · Cited by 29
Anacetrapib and Dalcetrapib: Two Novel Cholesteryl Ester Transfer Protein Inhibitors
Miyares, M. A. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p446 · Cited by 29
New Approaches in Detection and Treatment of Familial Hypercholesterolemia
Hartgers, M. L., Ray, K. K., & Hovingh, G. K. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0665-x · Cited by 29
Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation
Yamashita, S., & Matsuzawa, Y. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000332 · Cited by 30
Pharmacological management of diabetic dyslipidemia
Filippatos, T. D., Florentin, M., Georgoula, M., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1263565 · Cited by 29
Evacetrapib
Eyvazian, V. A., & Frishman, W. H. (2017) · Cardiology in Review · doi:10.1097/crd.0000000000000137 · Cited by 31
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?
Barter, P. J., Nicholls, S. J., Kastelein, J. J. P., & Rye, K.-A. (2015) · Circulation · doi:10.1161/circulationaha.114.014025 · Cited by 31
Self-citation
Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010
Gensch, C., Hoppe, U. C., Böhm, M., & Laufs, U. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0270-3 · Cited by 29
Gene Therapy Targeting LDL Cholesterol but not HDL Cholesterol Induces Regression of Advanced Atherosclerosis in a Mouse Model of Familial Hypercholesterolemia
Li, R., & Chao, H. (2011) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000106 · Cited by 29
Drug Discovery and Development
Blass, B. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411508-8.00001-3 · Cited by 33
Causal Effect of Lipids and Lipoproteins on Atherosclerosis
Ference, B. A. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.001 · Cited by 28
Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future
Stein, E. A., & Raal, F. J. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0659-8 · Cited by 28
Niacin: the only vitamin that reduces cardiovascular events
Wierzbicki, A. S. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02630.x · Cited by 28
Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes
Turner, T. A., & Stein, E. A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.004 · Cited by 28
Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease
Stein, E. A., & Raal, F. J. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6654-5 · Cited by 29
Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease
Hu, J., Lei, H. C., Liu, L., & Xu, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.812368 · Cited by 28
10-Dehydrogingerdione raises HDL-cholesterol through a CETP inhibition and wards off oxidation and inflammation in dyslipidemic rabbits
Elseweidy, M. M., Abdallah, F. R., Younis, N. N., Aldohmy, S., & Kassem, H. M. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.024 · Cited by 28
From Treating Complex Coronary Artery Disease to Promoting Cardiovascular Health: Therapeutic Transitions and Challenges, 2010–2020
Kovacic, J. C., & Fuster, V. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.173 · Cited by 29
Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy
Iannuzzo, G., Tripaldella, M., Mallardo, V., Morgillo, M., Vitelli, N., Iannuzzi, A., Aliberti, E., Giallauria, F., Tramontano, A. L., Carluccio, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9070838 · Cited by 29
Lipoprotein(a)
Koschinsky, M. L., & Boffa, M. B. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.002 · Cited by 28
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?
Barter, P. J., & Rye, K. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.004 · Cited by 27
Self-citation
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial
Brinton, E. A., Kher, U. A., Shah, S., Cannon, C. P., Davidson, M. H., Gotto, A. M., Ashraf, T. B., Sisk, C. M., Dansky, H. M., Mitchel, Y., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.10.005 · Cited by 27
Self-citation
Potent Cholesteryl Ester Transfer Protein Inhibitors of Reduced Lipophilicity: 1,1′-Spiro-Substituted Hexahydrofuroquinoline Derivatives
Trieselmann, T., Wagner, H., Fuchs, K. P., Hamprecht, D. W., Berta, D. G., Cremonesi, P., Streicher, R., Luippold, G., Volz, A., Markert, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500431d · Cited by 27
Novel lipid modifying drugs to lower LDL cholesterol
Cupido, A. J., Reeskamp, L. F., & Kastelein, J. J. P. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000428 · Cited by 30
Pathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis
Shah, S. M., Shah, J., Lakey, S., Garg, P., & Ripley, D. P. (2023) · Open Heart · doi:10.1136/openhrt-2022-002244 · Cited by 32
Self-citation
HDL-C: Does it matter? An update on novel HDL-directed pharmaco-therapeutic strategies
Gadi, R., Amanullah, A. M., & Figueredo, V. M. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.052 · Cited by 27
What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
Hung, M., & Tsimikas, S. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000131 · Cited by 27
Genetic determination of lipoprotein(a) and its association with cardiovascular disease: convenient does not always mean better
Kronenberg, F. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12207 · Cited by 27
Novel HDL-based therapeutic agents
JOY, T. R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.03.004 · Cited by 26
Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety
Yadav, R., France, M. W., Younis, N., Hama, S., Ammori, B. J., Kwok, S., & Soran, H. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.690395 · Cited by 27
Inherited Variants in SCARB1 Cause Severe Early-Onset Coronary Artery Disease
Koenig, S. N., Sucharski, H. C., Jose, E. M., Dudley, E. K., Madiai, F., Cavus, O., Argall, A. D., Williams, J. L., Murphy, N. P., Keith, C. B. R., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.318793 · Cited by 27

Authors: Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., Zafarino, J., Mitchel, Y., & Barter, P.
Affiliations: Brigham and Women's Hospital (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Radiant Research (United States) (US)
University of Utah (US)
The Heart Research Institute (AU)
ORCID: Cannon, Christopher P.
Dansky, Hayes M.
Davidson, Michael
Brinton, Eliot A.
Gotto, Antonio M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2010-12-16
Volume: 363
Issue: 25
Pages: 2406-2415
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1009744
OpenAlex: W2090464684
Cited by: 749
References: 17
Citations by year: 2026: 13 · 2025: 7 · 2024: 13 · 2023: 13 · 2022: 16 · 2021: 18 · 2020: 18 · 2019: 21 · 2018: 26 · 2017: 54 · 2016: 68 · 2015: 83 · 2014: 83 · 2013: 92 · 2012: 116
FWCI: 107.18
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords: anacetrapib, cholesteryl ester transfer protein inhibitors, coronary artery disease, LDL cholesterol lowering, HDL cholesterol, statin combination therapy, cardiovascular safety, cardiovascular events, drug safety, high-risk patients, lipid-lowering therapy, blood pressure, electrolytes, aldosterone, Bayesian hierarchical model, cardiovascular hospitalization
MeSH terms: Adult, Aged, Anticholesteremic Agents, Bayes Theorem, Combined Modality Therapy, Coronary Disease, Double-Blind Method, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Oxazolidinones, Cholesterol Ester Transfer Proteins, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks